These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36942494)

  • 1. Effects of angiotensin receptor-neprilysin inhibitor on insulin resistance in patients with heart failure.
    Kashiwagi Y; Nagoshi T; Kimura H; Tanaka Y; Oi Y; Inoue Y; Ogawa K; Kawai M; Yoshimura M
    ESC Heart Fail; 2023 Jun; 10(3):1860-1870. PubMed ID: 36942494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world experience of angiotensin receptor neprilysin inhibitor on the glucose-lowering effect.
    Kim H; Park G; Hahn J; Oh J; Chang MJ
    Sci Rep; 2022 Jun; 12(1):9703. PubMed ID: 35690600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin Receptor Neprilysin Inhibitor Use and Blood Pressure Lowering in Patients With Heart Failure With Reduced Ejection Fraction Across the Spectrum of Kidney Function: An Analysis of the Veterans Administrative Health System.
    Gjyriqi G; York M; Abuazzam F; Herzog CA; Bangalore S; Lo KB; Sidhu MS; Vaduganathan M; Rangaswami J; Mathew RO
    J Card Fail; 2023 Mar; 29(3):258-268. PubMed ID: 36516938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term impact of angiotensin receptor-neprilysin inhibitor based on short-term treatment response in heart failure.
    Park HK; Park JS; Kim MS; Lee E; Choi H; Park YJ; Park BE; Kim HN; Kim N; Bae MH; Lee JH; Park HS; Cho Y; Jang SY; Yang DH
    ESC Heart Fail; 2023 Dec; 10(6):3430-3437. PubMed ID: 37705397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction.
    Park DY; An S; Attanasio S; Jolly N; Malhotra S; Doukky R; Samsky MD; Sen S; Ahmad T; Nanna MG; Vij A
    Am J Cardiol; 2023 Jan; 187():84-92. PubMed ID: 36459752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of angiotensin receptor-neprilysin inhibitor on ketone body metabolism in pre-heart failure/heart failure patients.
    Kashiwagi Y; Nagoshi T; Tanaka Y; Oi Y; Kimura H; Ogawa K; Kawai M; Yoshimura M
    Sci Rep; 2024 Jul; 14(1):16493. PubMed ID: 39020009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure.
    Sun Y; Song S; Zhang Y; Mo W; Zhang X; Wang N; Xia Y; Tse G; Liu Y
    ESC Heart Fail; 2022 Feb; 9(1):667-675. PubMed ID: 34779134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
    Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Socioeconomic Determinants of Angiotensin Receptor-Neprilysin Inhibitor Prescription at Hospital Discharge in Patients With Heart Failure With Reduced Ejection Fraction.
    Tran JS; Loveland MG; Alamer A; Piña IL; Sweitzer NK
    Circ Heart Fail; 2022 Nov; 15(11):e009395. PubMed ID: 36378759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
    Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction.
    Fu M; Pivodic A; Käck O; Costa-Scharplatz M; Dahlström U; Lund LH
    Clin Res Cardiol; 2023 Jan; 112(1):167-174. PubMed ID: 36443599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure.
    Arfsten H; Goliasch G; Bartko PE; Prausmüller S; Spinka G; Cho A; Novak J; Haslacher H; Strunk G; Struck J; Hülsmann M; Pavo N
    Br J Clin Pharmacol; 2021 Mar; 87(3):916-924. PubMed ID: 32598074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical benefits of angiotensin receptor-Neprilysin inhibitor in adults with congenital heart disease.
    Andi K; Abozied O; Miranda WR; Anderson JH; Connolly HM; Jain CC; Burchill LJ; Egbe AC
    Int J Cardiol; 2023 Sep; 387():131152. PubMed ID: 37429446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart Failure Treatments Such As Angiotensin Receptor/Neprilysin Inhibitor Improve Heart Failure Status and Glucose Metabolism.
    Kashiwagi Y; Nagoshi T; Ogawa K; Kawai M; Yoshimura M
    Cureus; 2022 Mar; 14(3):e22762. PubMed ID: 35371876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States.
    Yan BW; Spahillari A; Pandya A
    Circ Cardiovasc Qual Outcomes; 2023 Jun; 16(6):e009793. PubMed ID: 37278232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Retrospective Cohort Evaluation of a Pharmacist-Led Approach for Transitioning Patients to an Angiotensin Receptor-Neprilysin Inhibitor.
    Rana K; Jay J; Patel S; Sueta C; Deyo Z
    J Pharm Pract; 2023 Oct; 36(5):1061-1067. PubMed ID: 35392695
    [No Abstract]   [Full Text] [Related]  

  • 18. Real-World Experience of Angiotensin Receptor-Neprilysin Inhibition in Reduced Ejection Fraction Heart Failure Patients With Advanced Kidney Disease.
    Chang HY; Lin CC; Chao CJ; Lin YC; Wang YC; Liao CT; Huang JL; Lee YH; Huang CY; Chien LN; Hsu CY
    Mayo Clin Proc; 2023 Jan; 98(1):88-99. PubMed ID: 36109207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction.
    Khariton Y; Fonarow GC; Arnold SV; Hellkamp A; Nassif ME; Sharma PP; Butler J; Thomas L; Duffy CI; DeVore AD; Albert NM; Patterson JH; Williams FB; McCague K; Spertus JA
    JACC Heart Fail; 2019 Nov; 7(11):933-941. PubMed ID: 31521679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of angiotensin receptor-neprilysin inhibitor and sodium-glucose cotransporter-2 inhibitors for patients with heart failure with reduced ejection fraction: a meta-analysis.
    Huang Y; Fang C; Zhang Y; Ma L; Zhou H; Ye H
    J Cardiovasc Med (Hagerstown); 2023 Feb; 24(2):123-131. PubMed ID: 36583980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.